Naslov
Drug Treatment of Metabolic Syndrome

Autori
Altabas, Velimir

Izvornik
Current clinical pharmacology (1574-8847) 8 (2013), 3; 224-231

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo

Ključne riječi
INSULIN-RESISTANCE ; BLOOD-PRESSURE ; WEIGHT-LOSS ; LONG-TERM ; CARDIOVASCULAR PROTECTION ; HYPERTENSIVE PATIENTS ; DIABETES-MELLITUS ; ACE-INHIBITORS ; IN-VIVO ; ORLISTAT

Sažetak
The metabolic syndrome is a constellation of risk factors for cardiovascular diseases including: abdominal obesity, a decreased ability to metabolize glucose (increased blood glucose levels and/or presence of insulin resistance), dyslipidemia, and hypertension. Patients who have developed this syndrome have been shown to be at an increased risk of developing cardiovascular disease and/or type 2 diabetes. Genetic factors and the environment both are important in the development of the metabolic syndrome, influencing all single components of this syndrome. The goals of therapy are to treat the underlying cause of the syndrome, to reduce morbidity, and to prevent complications, including premature death. Lifestyle modification is the preferred first-step treatment of the metabolic syndrome. There is no single effective drug treatment affecting all components of the syndrome equally known yet. However, each component of metabolic syndrome has independent goals to be achieved, so miscellaneous types of drugs are used in the treatment of this syndrome, including weight losing drugs, antidiabetics, antihypertensives, antilipemic and anticlothing drugs etc. This article provides a brief insight into contemporary drug treatment of components the metabolic syndrome.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA